Healthcare provider profile · identity verified

Melissa Harrold, MD

Internal Medicine · COLUMBUS, OH · NPI 1245271899

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	253	77
Levothyroxine Sodium	Levothyroxine Sodium	153	41
Amlodipine Besylate	Amlodipine Besylate	136	39
Lisinopril	Lisinopril	130	36
Gabapentin	Gabapentin	112	29
Losartan Potassium	Losartan Potassium	87	25
Simvastatin	Simvastatin	79	22
Omeprazole	Omeprazole	74	23
Rosuvastatin Calcium	Rosuvastatin Calcium	69	19
Atenolol	Atenolol	66	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	65	suppressed
Synthroid	Levothyroxine Sodium	58	17
Alprazolam	Alprazolam	57	14
Metformin Hcl	Metformin Hcl	53	17
Metoprolol Succinate	Metoprolol Succinate	53	16
Trazodone Hcl	Trazodone Hcl	53	14
Oxycontin	Oxycodone Hcl	52	suppressed
Bupropion Xl	Bupropion Hcl	49	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	49	16
Albuterol Sulfate Hfa	Albuterol Sulfate	46	21
Sertraline Hcl	Sertraline Hcl	45	13
Duloxetine Hcl	Duloxetine Hcl	43	12
Allopurinol	Allopurinol	42	11
Furosemide	Furosemide	42	17
Spironolactone	Spironolactone	41	12
Escitalopram Oxalate	Escitalopram Oxalate	40	13
Fluoxetine Hcl	Fluoxetine Hcl	40	11
Fluticasone Propionate	Fluticasone Propionate	40	17
Ozempic	Semaglutide	39	suppressed
Famotidine	Famotidine	36	12
Montelukast Sodium	Montelukast Sodium	35	13
Tramadol Hcl	Tramadol Hcl	35	suppressed
Carvedilol	Carvedilol	33	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	33	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Potassium Chloride	Potassium Chloride	31	11
Ezetimibe	Ezetimibe	30	suppressed
Eliquis	Apixaban	29	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	28	22
Celecoxib	Celecoxib	26	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	25	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	20
Meloxicam	Meloxicam	22	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	12
Azithromycin	Azithromycin	19	12
Lorazepam	Lorazepam	19	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	16
Trulicity	Dulaglutide	16	suppressed
Amiloride Hcl	Amiloride Hcl	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Nystatin	Nystatin	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Prednisone	Prednisone	14	12
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Vraylar	Cariprazine Hcl	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Topiramate	Topiramate	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error